{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-076474","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.954686+00:00","generated_at":"2026-06-01T02:31:48.967540+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Erasca initiates global Phase 3 SEACRAFT-2 trial for naporafenib + trametinib in NRAS-mutant melanoma","bullets":["SEACRAFT-2 evaluates pan-RAF inhibitor naporafenib plus MEK inhibitor trametinib vs trametinib alone.","Stage 1 of the Phase 3 trial is expected to yield a randomized data readout in 2025.","Trial targets NRAS-mutant melanoma, a setting with limited approved targeted therapies.","Initiation marks the first Phase 3 trial for Erasca's wholly owned candidate naporafenib."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-076474","json":"https://secwatch.observer/filing/0000950170-24-076474.json","markdown":"https://secwatch.observer/filing/0000950170-24-076474.md","text":"https://secwatch.observer/filing/0000950170-24-076474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024076474/0000950170-24-076474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017024076474/eras-20240618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:31:48.967540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}